---
title: "Rallybio Corporation (RLYB.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RLYB.US.md"
symbol: "RLYB.US"
name: "Rallybio Corporation"
industry: "Biotechnology"
datetime: "2026-06-10T11:13:46.516Z"
locales:
  - [en](https://longbridge.com/en/quote/RLYB.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RLYB.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RLYB.US.md)
---

# Rallybio Corporation (RLYB.US)

## Company Overview

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.rallybio.com](https://www.rallybio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-06-10T04:30:17.000Z

**Overall: C (0.51)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 150 / 390 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1.18% |  |
| Net Profit YoY | 83.78% |  |
| P/B Ratio | 1.67 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 84158729.25 |  |
| Revenue | 858000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -14.98% | E |
| Profit Margin | -911.07% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | 1.18% | C |
| Net Profit YoY | 83.78% | A |
| Total Assets YoY | -6.06% | D |
| Net Assets YoY | -7.02% | D |
| Cash Flow Margin | 352.90% | A |
| OCF YoY | 1.18% | C |
| Turnover | 0.02 | E |
| Gearing Ratio | 7.70% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Rallybio Corporation",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "1.18%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "83.78%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.67",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "84158729.25",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "858000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-14.98%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-911.07%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "1.18%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "83.78%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-6.06%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-7.02%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "352.90%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "1.18%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.02",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "7.70%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -10.77 | 459/390 | - | - | - |
| PB | 1.67 | 168/390 | 0.78 | 0.50 | 0.41 |
| PS (TTM) | 98.09 | 256/390 | 53.21 | 40.12 | 29.37 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | CapForce Inc. (CFOR.US) | A | A | A | A | B | A |
| 05 | OpGen (OPGN.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-10T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Hold | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 15.91 |
| Highest Target | 8.00 |
| Lowest Target | 8.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/RLYB.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/RLYB.US/norm.md)
- [Related News](https://longbridge.com/en/quote/RLYB.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/RLYB.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**